DDInter1881 DDInter1747
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramelteon
Troglitazone {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Troglitazone may lead to a major life threatening interaction when taken with Mipomersen